Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

Oral Cavity Oropharyngeal Cancer

Partnership to Intercept Oral Cavity/Oropharyngeal Cancer

The Disease Interception Accelerator established a partnership with UbiVac, a privately held, clinical-stage, immuno-oncology company for the development of an immunotherapy that is intended to intercept oral cavity/oropharyngeal cancer.

Partnerships

Partnerships

Wendy Olsen, lincs
Wendy Olsen, lincs

Disease Interception Accelerator

Disease Interception Accelerator

Oncology

Oncology

Human lung bronchioalveolar carcinoma cell

World Without Disease Accelerator

World Without Disease Accelerator

istock